Health data flows one direction, with no guarantee of access to resulting innovations.
In the long history of aid as instrument, the Trump administration has formalized what was once merely implied: that health assistance and resource access are two faces of the same coin. Across 32 nations — 22 of them in sub-Saharan Africa — bilateral health agreements worth at least $20 billion quietly bind epidemic surveillance, pharmaceutical markets, and co-financing obligations to the geopolitical ambitions of a nation in search of cobalt, lithium, and rare earths. The question these agreements pose is ancient and unresolved: when the powerful offer care, who truly bears the cost?
- Washington has signed 32 health agreements with mineral-rich developing nations, embedding resource access and strategic leverage directly into the architecture of humanitarian aid.
- Partner governments must report epidemics to Washington within 48 hours, favor American pharmaceutical companies, and progressively absorb funding responsibilities — or risk losing assistance entirely.
- Zambia and Zimbabwe have refused the terms as unacceptable, but most African nations, deeply dependent on external health financing, have found themselves with little practical room to push back.
- The simultaneous dismantling of USAID and U.S. withdrawal from the WHO have removed decades of institutional capacity with no replacement in sight, leaving vulnerable populations exposed.
- African health advocates and analysts are pointing toward domestic budget commitments, local pharmaceutical development, and South-South cooperation as the only durable path out of structural dependence.
Since releasing its 'America First Global Health Strategy,' the Trump administration has signed 32 bilateral health agreements with developing nations — 22 of them in sub-Saharan Africa — representing at least $20 billion in pledged funding through 2030. An analysis by the Institute for International and Strategic Affairs found a striking pattern: nearly every signatory country holds significant reserves of the critical minerals Washington needs most, from cobalt and lithium to copper and rare earths. The Democratic Republic of Congo stands as the sharpest illustration, where a health agreement signed in early 2026 sits visibly within a broader American effort to protect extractive interests and influence the country's internal conflicts.
The agreements carry three layers of conditions that reveal their underlying logic. Signatory nations must report epidemic outbreaks to Washington within 48 hours, creating a parallel surveillance channel outside multilateral frameworks. The deals are structured to favor American pharmaceutical companies, extending the 'Buy American' doctrine into global health markets. And most agreements were concluded without public consultation or parliamentary debate, under what analysts describe as deeply unequal negotiating conditions.
The financial design compounds the imbalance. Partner governments are required to increase their own health spending over the agreement period while American contributions gradually decline — and failure to meet co-financing targets gives Washington the right to suspend funding entirely. For nations already stretched across competing development needs, this mechanism converts co-financing into a form of structural dependence. Zambia and Zimbabwe rejected the terms outright, but most African governments, heavily reliant on external health funding, had little leverage to refuse.
The human cost is not abstract. Countries that report epidemic data to Washington within 48 hours carry no guarantee of affordable access to the vaccines or treatments that data may help produce. Meanwhile, the hollowing out of USAID and the American exit from the WHO have created a gap that neither China nor any other actor has yet moved to fill at comparable scale.
Analysts argue that Africa's most resilient path forward is not a search for alternative patrons but the construction of indigenous capacity — raising domestic health budgets toward the 15 percent target set by the 2001 Abuja Declaration, investing in local pharmaceutical industries, deepening cooperation among African states, and insisting on genuine partnership in any future agreements. Whether the political will and continental coordination required for that shift can be sustained remains the defining challenge ahead.
The Trump administration has woven health assistance into the fabric of its broader competition for global influence and resources. Since publishing its "America First Global Health Strategy" last September, the administration has signed 32 bilateral health agreements with developing nations, including 22 documented deals across sub-Saharan Africa, with negotiations still underway in other countries. These multiyear commitments represent at least $20 billion in pledged funding through 2030, though only a fraction of the terms have been made public.
A geopolitical analysis released this week by the Institute for International and Strategic Affairs found a striking pattern: nearly all 32 countries that signed these agreements are rich in the mineral resources Washington increasingly needs—cobalt, lithium, copper, and rare earths essential for clean energy, defense systems, and advanced technology. The list includes Mozambique, Nigeria, Angola, Rwanda, Cameroon, Botswana, and Côte d'Ivoire. The Democratic Republic of Congo stands as the clearest example of this strategy at work. The health agreement signed with Kinshasa in early 2026 extends far beyond public health objectives, the analysis notes, and sits within a larger American effort to protect extractive interests while simultaneously wielding influence over the country's internal conflicts, particularly the dispute involving Rwanda and the M23 rebel group.
The agreements themselves contain three categories of conditions that reveal their true architecture. First, signatory countries must report any epidemic outbreak to Washington within 48 hours—a requirement that creates a parallel reporting channel outside existing international mechanisms and raises questions about coordination with multilateral standards. Second, the deals appear designed to strengthen the position of American pharmaceutical companies like Gilead Sciences, which produces Lenacapavir, a long-acting HIV treatment. The "Buy American" logic embedded in U.S. foreign policy extends directly into global health. Third, most agreements were signed without public consultation or parliamentary debate in the countries involved, and their full terms remain unpublished despite what the analysis describes as deeply unequal negotiating conditions.
The financial architecture creates what amounts to permanent leverage. The strategy explicitly requires partner governments to increase their own health spending throughout the agreement period, while the American contribution gradually declines. If countries fail to meet their co-financing obligations, Washington can reduce or suspend funding entirely. For nations already stretched thin by competing development needs, this mechanism transforms co-financing into a tool of structural dependence. Zambia and Zimbabwe have already rejected these agreements as unbalanced, but most African countries, heavily reliant on external health funding, have had little room to refuse.
The human stakes are substantial. African nations carry some of the world's highest burdens of infectious disease, yet the agreements provide no guarantee that countries will gain access to the medical innovations their health data helps generate. A country reporting an epidemic to Washington within 48 hours may never see the resulting vaccine or treatment at an affordable price. Meanwhile, the dismantling of USAID and the American withdrawal from the World Health Organization have created a vacuum that no other actor can easily fill. China has signaled willingness to increase support to the WHO, but Beijing has not yet become the organization's primary funder. The financial volumes, operational presence, and sector expertise built over two decades of American investment cannot be quickly replaced.
The analysis suggests that Africa's most sustainable path forward lies not in finding alternative external funders but in building indigenous capacity. The Lusaka Agenda, the African Medicines Agency, and the Accra Summit on Health Sovereignty point toward a different model—one based on African-led reform rather than dependence on bilateral deals. Four concrete levers exist: increasing domestic health budgets toward the 15 percent target set in the 2001 Abuja Declaration (most African nations currently allocate around 7 percent); supporting local pharmaceutical industries; strengthening cooperation among African nations themselves; and negotiating future agreements on the basis of genuine partnership rather than subordination. But these mechanisms will require sustained political will and stronger coordination among African Union member states—a challenge that may prove as difficult as the agreements themselves.
Notable Quotes
Health assistance has become one instrument among others in the race for strategic resources, while one of Washington's broader objectives is to counter China's dominant position.— Institute for International and Strategic Affairs analysis
No actor today possesses the financial volumes, operational presence and sector expertise that 20 years of U.S. investment had built.— IRIS analysis on the gap left by USAID dismantling and WHO withdrawal
The Hearth Conversation Another angle on the story
So these health agreements—are they actually about health, or is that just the cover story?
They're genuinely about health, but health is being used as one instrument among many. The U.S. is providing real funding for real diseases. The problem is that the terms of the deal tie that assistance directly to access to minerals and geopolitical positioning. It's not a lie; it's a layering.
Why does the 48-hour reporting requirement matter so much? Isn't faster disease reporting good?
Faster reporting is good in principle. But creating a separate channel to Washington, outside the existing international systems, fragments the global response. It also means African countries are giving the U.S. early warning of health crises without any guarantee they'll benefit from what the U.S. learns. The data flows one direction.
The co-financing trap—explain that more clearly.
A country agrees to put in its own money alongside American funding. But the American contribution shrinks over time, and if the country can't keep up its share, the U.S. can pull out entirely. For a poor country, that's a noose that tightens. You're forced to choose between health spending and everything else.
Why would any country sign these deals?
Because they're desperate. When you're dealing with malaria, tuberculosis, and HIV, and you don't have the domestic resources to fight them, you take what's offered. The negotiating power is completely asymmetrical. You can refuse, but your people suffer.
Is there a way out of this?
Yes, but it's slow and requires African countries to invest in themselves—building their own pharmaceutical industries, their own research capacity, their own health systems. It also means African nations working together instead of competing for scraps from external powers. That's harder than signing a bilateral agreement, but it's the only path to actual sovereignty.
And if they don't take that path?
Then they remain locked in these relationships indefinitely, always dependent, always negotiating from weakness, always watching their health data and resources flow outward while the benefits flow back to Washington and American companies.